Role of soluble epoxide hydrolase in pain and depression comorbidity

Bu, Yuchen; Yang, Siqi; Wang, Di; Hu, Suwan; Zhang, Qi; Wu, Zifeng; Yang, Chun

doi:10.1016/j.nbd.2024.106443

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders

Zhao,

Yang,

Hashimoto

2024

Advances in Pharmacology

View full text Add to dashboard Cite

Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders

Zhao,

Yang,

Hashimoto

2024

Advances in Pharmacology

View full text Add to dashboard Cite

Special issue on “A focus on brain–body communication in understanding the neurobiology of diseases”

Hashimoto,

Wei,

Yang

2024

Neurobiology of Disease

View full text Add to dashboard Cite

Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain

Babkov,

Eliseeva,

Adzhienko

et al. 2024

IJMS

View full text Add to dashboard Cite

Inhibition of soluble epoxide hydrolase (sEH) is a promising therapeutic strategy for treating neuropathic pain. These inhibitors effectively reduce diabetic neuropathic pain and inflammation induced by Freund’s adjuvant which makes them a suitable alternative to traditional opioids. This study showcased the notable analgesic effects of compound AMHDU (1,1′-(hexane-1,6-diyl)bis(3-((adamantan-1-yl)methyl)urea)) in both inflammatory and diabetic neuropathy models. While lacking anti-inflammatory properties in a paw edema model, AMHDU is comparable to celecoxib as an analgesic in 30 mg/kg dose administrated by intraperitoneal injection. In a diabetic tactile allodynia model, AMHDU showed a prominent analgesic activity in 10 mg/kg intraperitoneal dose (p < 0.05). The effect is comparable to that of gabapentin, but without the risk of dependence due to a different mechanism of action. Low acute oral toxicity (>2000 mg/kg) and a high therapeutic index makes AMHDU a promising candidate for further structure optimization and preclinical evaluation.

show abstract

Role of soluble epoxide hydrolase in pain and depression comorbidity

Cited by 3 publications

References 141 publications

Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders

Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders

Special issue on “A focus on brain–body communication in understanding the neurobiology of diseases”

Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain

Contact Info

Product

Resources

About